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Olanzapine Sensitization and Clozapine Tolerance: From
Adolescence to Adulthood in the Conditioned Avoidance
Response Model
Jing Qiao1,2, Hong Li1,3 and Ming Li*,2
1Key Laboratory of Cognition and Personality (Southwest University), Ministry of Education, Institute of Psychology, Southwest University,
Chongqing, China; 2Department of Psychology, University of Nebraska-Lincoln, Lincoln, NE, USA
Disruption of conditioned avoidance response (CAR) in rodents is one trademark feature of many antipsychotic drugs. In adult rats,
repeated olanzapine (OLZ) treatment causes an enhanced disruption of avoidance response (sensitization), whereas repeated clozapine
(CLZ) treatment causes a decreased disruption (tolerance). The present study addressed (1) whether OLZ sensitization and CLZ
tolerance can be induced in adolescent rats, and (2) the extent to which OLZ sensitization and CLZ tolerance induced in adolescence
persists into adulthood. Male adolescent Sprague–Dawley rats (approximate postnatal days (BP) 43–47) were first treated with OLZ
(1.0 or 2.0mg/kg, subcutaneously (sc)) or CLZ (10 or 20mg/kg, sc) daily for 5 consecutive days in the CAR model. They were then
tested for the expression of OLZ sensitization or CLZ tolerance either in adolescence (BP 50) or after they matured into adults (BP 76
and 92) in a challenge test during which all rats were injected with either a lower dose of OLZ (0.5mg/kg) or CLZ (5.0mg/kg). When
tested in adolescence, rats previously treated with OLZ showed a stronger inhibition of CAR than those previously treated with vehicle
(ie, sensitization). In contrast, rats previously treated with CLZ showed a weaker inhibition of CAR than those previously treated with
vehicle (ie, tolerance). When tested in adulthood, the OLZ sensitization was still detectable at both time points (BP 76 and 92),
whereas the CLZ tolerance was only detectable on BP 76, and only manifested in the intertrial crossing. Performance in the prepulse
inhibition and fear-induced 22 kHz ultrasonic vocalizations in adulthood were not altered by adolescence drug treatment. Collectively,
these findings suggest that atypical antipsychotic treatment during adolescence can induce a long-term specific alteration in antipsychotic
effect that persists into adulthood despite the brain maturation. As antipsychotic drugs are being increasingly used in children and
adolescents in the past two decades, findings from this study are important for understanding the impacts of adolescent antipsychotic
treatment on the brain and behavioral developments. This work also has implications for clinical practice involving adolescence
antipsychotic treatments in terms of drug choice, drug dose, and schedule.
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INTRODUCTION
Antipsychotic drugs are the primary medications used to
treat psychosis. Like many other psychoactive drugs,
repeated administration of these drugs often induces
various clinically relevant sensitization and tolerance effects
in many behavioral domains (Emmett-Oglesby and Goudie,
1989). The specific long-term patterns (ie, sensitization or
tolerance) of antipsychotic treatment appear to depend on
several factors, including classes of drugs, treatment
schedule, drug dose, and behavioral testing conditions
(Barnes et al, 1990; Remington and Kapur, 2010).
In recent years, we have used the conditioned avoidance
response (CAR) and phencyclidine (PCP)-induced hyperlo-
comotion, two models with high predictive validity for
antipsychotic efficacy (Gleason and Shannon, 1997; Natesan
et al, 2005; Wadenberg, 2010), to examine the long-term
treatment effects of antipsychotic drugs. We employed a
behavioral paradigm similar to those used for the study of
psychomotor sensitization (Stewart and Badiani, 1993;
Robinson et al, 1998). First, rats are repeatedly treated with
an antipsychotic drug or vehicle for a certain number of
days (eg, 5 or 7 days), and their avoidance responses and
PCP-induced hyperlocomotion are recorded. This period is
termed the induction phase. A few days later, all rats are
given a challenge dose of the drug to assess the expression
of antipsychotic sensitization or tolerance (termed the
expression phase). In the induction phase, antipsychotic
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sensitization or tolerance is observed if the avoidance-
disruptive effect or the inhibitory effect on PCP-induced
hyperlocomotion of the drug increases or decreases in
magnitude throughout the treatment period. In the expres-
sion phase, sensitization or tolerance is shown if the drug-
treated animals exhibit a stronger (ie, less avoidance
responses or lower PCP-induced hyperlocomotion) or
weaker response (ie, more avoidance responses or higher
PCP-induced hyperlocomotion) than the vehicle-treated
ones (Li et al, 2010).
Using such a paradigm, we show that repeated treat-
ment of haloperidol and olanzapine (OLZ) induce a
sensitization effect in both the induction and expression
phases (Li et al, 2009b; Li et al, 2009a; Sun et al, 2009;
Li et al, 2010; Mead and Li, 2010; Zhao et al, 2012).
In contrast, repeated treatment of clozapine (CLZ) does not
cause an apparent sensitization or tolerance during
the induction phase (Sun et al, 2009; Li et al, 2010). But
in the expression phase when all rats are injected with a low
dose of CLZ, rats previously treated with CLZ exhibit a
tolerance effect, as they often make significantly more
avoidance responses and exhibit higher PCP-induced
hyperlocomotion than those that are treated with CLZ for
the first time (Li et al, 2010).
So far, all the antipsychotic sensitization and tolerance
studies have been done in adult rats. One interesting and
important question arises: if an antipsychotic drug is
administered to adolescent rats (35–60 days old; Andersen
et al, 2000) for a certain number of days, after they become
adults, will they still show an enhanced (sensitization) or
decreased (tolerance) response to the drug? The answer to
this question will not only increase our understanding of
the behavioral mechanisms involved in antipsychotic
treatment, but also allow us to study the long-term impacts
of such exposure to antipsychotic drugs on brain develop-
ment and behavioral functions. The present study reports
our investigation of the OLZ sensitization and CLZ
tolerance in the CAR model across the adolescence and
adulthood periods. Similar results have been found in the
PCP-induced hyperlocomotion model (unpublished obser-
vations). As sensitization and tolerance often develop to a
particular effect of a drug, but not to a drug itself, in order
to assess the behavioral specificity of OLZ sensitization and
CLZ tolerance, we also examined their effects on 22 kHz
ultrasonic vocalization (USV, a measure of fear/anxiety;
Mead et al, 2008; Sun et al, 2010) and on intertrial crossing
in the CAR task (a putative measure of motor function/
sedation). In addition, we examined the prepulse inhibition
(PPI) of acoustic startle response of the rats periodically
throughout their developmental period (approximate
postnatal days, (BP) 43–47) as a way to assess how
adolescence antipsychotic treatment affects the brain and
behavioral functions and development of adolescent rats.
PPI refers to the phenomenon of a reduction in the startle
magnitude when the startling stimulus is preceded by a low-
intensity prepulse. It measures the sensorimotor gating
ability, a basic pre-attentive cognitive function, which is
impaired in patients with schizophrenia and in animals
acutely treated with dopamine agonists and NMDA
antagonists (Geyer and Braff, 1987; Swerdlow et al, 2008).
This task was chosen also because adolescence antipsycho-
tic treatment has been found to cause an impairment of PPI
performance under certain conditions (Meyer et al, 2010;
Llorente-Berzal et al, 2012).
MATERIALS AND METHODS
Animals
Male Sprague–Dawley adolescent rats from Charles River
(Portage, MI; P 22–26, averaged age was assumed at P 24,
51–75 g on delivery date) were used. They were housed two
per cage, in 48.3 26.7 20.3 cm transparent polycarbonate
cages under 12 h light/dark conditions (light on between
0630 and 1830 h). Room temperature was maintained at
22±1 1C with a relative humidity of 45–60%. Food and
water was available ad libitum. Animals were allowed at
least 5 days of habituation to the animal facility before being
used in experiments (BP 31). All procedures were appro-
ved by the Institutional Animal Care and Use Committee at
the University of Nebraska-Lincoln.
Drugs and Choice of Doses
Both OLZ and CLZ (gifts from the NIMH drug supply
program) were dissolved in distilled sterile water with 1.0–
1.5% glacial acetic acid. They were administrated subcuta-
neously (sc) at 1ml/kg. Two doses of OLZ (1.0 and 2.0mg/
kg) and CLZ (10 and 20mg/kg) were tested. These doses of
OLZ and CLZ produce a reliable and comparable disruption
on avoidance responding (Li et al, 2004; Li et al, 2007; Li
et al, 2009b; Li et al, 2010; Mead and Li, 2010; Zhang and Li,
2012). On the basis of data from the striatal dopamine D2
receptor occupancy study in rats (Kapur et al, 2003), we
estimated that both drugs at these doses would give rise to a
40–80% striatal D2 occupancy, which is comparable to values
observed in schizophrenic patients (Kapur et al, 1999).
Two-Way Avoidance Conditioning Apparatus
Eight identical two-way shuttle boxes custom-designed and
manufactured by Med Associates (St Albans, VT) were used.
Each box was housed in a ventilated, sound-insulated
isolation cubicle (96.52 cm W 35.56 cm D 63.5 cm H).
Each box was 64 cm long, 30 cm high (from grid floor), and
24 cm wide, and was divided into two equal-sized compart-
ments by a partition with an arch style doorway (15 cm
high 9 cm wide at base). A barrier (4 cm high) was placed
between the two compartments, so the rats had to jump
from one compartment to the other. The grid floor
consisted of 40 stainless-steel rods with a diameter of
0.48 cm, spaced 1.6 cm apart center to center, through which
a scrambled footshock (unconditioned stimulus, US,
0.8mA, maximum duration: 5 s) was delivered by a constant
current shock generator (Model ENV-410B) and scrambler
(Model ENV-412). The rat location and crossings between
compartments were monitored by a set of 16 photobeams
(ENV-256-8P) affixed at the bottom of the box (3.5 cm
above the grid floor). Illumination was provided by two
houselights mounted at the top of each compartment.
The conditioned stimulus (CS) (ie, 76 dB white noise) was
produced by a speaker (ENV 224 AMX) mounted on the
ceiling of the cubicle, centered above the shuttle box.
Background noise (approximately 74 dB) was provided by a
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ventilation fan affixed at the top corner of each isolation
cubicle. All training and testing procedures were controlled
by Med Associates programs running on a computer.
In each CAR box, an USV microphone (P 48/Emkay
Microphone, Avisoft Bioacoustics, Berlin, Germany) was
mounted on the ceiling of the two-compartment chamber.
The microphone was connected via an E-MU 0404 USB
Audio device to a computer. Acoustic data were displayed
in real time by the Avisoft RECORDER, a multi-channel
triggering hard-disk recording software (version 3.4; Avisoft
Bioacoustics), and were recorded at a sampling rate of
192 kHz in 16 bit format and analyzed by Avisoft SASLab
Pro (version 4.51; Avisoft Bioacoustics).
PPI of Acoustic Startle Reflex Apparatus
The PPI test was performed using six Startle Monitor Systems
(Kinder Scientific, Julian, CA). Each system, controlled by a
PC, was housed in a compact sound attenuation cabinet
(36 cm wide 28 cm deep 50 cm high). A speaker (dia-
meter: 11 cm) mounted on the cabinet’s ceiling was used to
generate acoustic stimuli (70–120dB). The startle response
was measured by a piezoelectric sensing platform on the
floor, which was calibrated daily. During testing, rats were
placed in a rectangular box made of transparent Plexiglas
(19 cm wide 9.8 cm deep 14.6 high) with an adjustable
ceiling positioned atop the box, providing only limited
restraint while prohibiting ambulation.
Experiment 1: OLZ Sensitization Induced in
Adolescence and Assessed in Adolescence
This experiment examined whether repeated OLZ treatment
could induce a sensitization effect in adolescent rats in the
CAR model as previously found in adult rats (Li et al, 2010;
Mead and Li, 2010; Li et al, 2012; Swalve and Li, 2012; Zhang
and Li, 2012). It consisted of three phases: avoidance training,
induction of OLZ sensitization, and sensitization assessment.
Avoidance training. Twenty-nine rats (BP 31) were first
habituated to the CAR boxes for 2 days (30min/day) and
then trained for conditioned avoidance responding for 10
consecutive days/sessions. Each session consisted of 30
trials. Every trial started by presenting a white noise (CS) for
10 s, followed by a continuous scrambled footshock (0.8mA,
US, maximum duration¼ 5 s) on the grid floor. If a subject
moved from one compartment into the other within the 10 s
of CS presentation, it avoided the shock, and this shuttling
response was recorded as ‘avoidance’. If the rat remained in
the same compartment for more than 10 s and made a
crossing upon receiving the footshock, this response was
considered as ‘escape’. If the rat did not respond during the
entire 5 s presentation of the shock, the trial was terminated
and ‘escape failure’ was recorded. The total number of
avoidance responses was recorded for each session. Intertrial
intervals varied randomly between 30 and 60 s.
Induction of OLZ sensitization. At the end of the training
session (BP 43), rats were first matched based on avoidance
performance on the last training day (ie, predrug) to create
blocks of rats (n¼ 3 rats/block) that were approximately
equal in performance. Within each block, they were then
randomly assigned to one of three groups: vehicle (sterile
water, n¼ 10), OLZ 1.0mg/kg (OLZ 1.0, n¼ 10), and OLZ
2.0mg/kg (OLZ 2.0, n¼ 9), and tested daily for avoidance
response for 5 consecutive days. The CS-only (no shock, 30
trials/daily session) condition was used to eliminate any
relearning effect caused by the presence of the US. During
each drug test, rats were first injected with OLZ or sterile
water. One hour later, they were placed in the CAR boxes and
tested. USVs at the 22 kHz range (20–32 kHz) were also
recorded for the first 10min of testing using Avisoft
Recorder software (Version 3.4). Settings included sampling
rate at 192 kHz, format 16 bit. For acoustical analysis,
recordings were transferred to Avisoft SASLab Pro (Version
4.51) and a fast Fourier transformation was conducted.
Spectrograms were generated with a fast Fourier transforma-
tion length of 256 points and a time window overlap of 50%
(100% Frame, FlatTop window). The spectrogram was
produced at a frequency resolution of 750Hz and a time
resolution of 0.6667ms. Call detection was provided by an
automatic single threshold-based algorithm (threshold:
–20dB) and a hold-time mechanism (hold time: 0.02 s). In
addition, the number of intertrial crossings (crossings during
the intertrial intervals) in each session was also recorded.
Sensitization assessment. One day after the last drug test
day, all rats were retrained drug-free for 1 day under the CS-
only (no shock;BP 48) condition and 1 day under the CS–
US condition (BP 49) to ensure all groups had a
comparable level of avoidance responding before the
sensitization assessment. OLZ sensitization was assessed 1
day later (BP 50) when all rats were injected with a
challenge dose of OLZ 0.5mg/kg and tested for avoidance
performance, 22 kHz USV, and intertrial crossings in the
CS-only condition (30 trials) 1 h later. This procedure of
using a lower challenge dose of OLZ has been successfully
used in our previous studies (Li et al, 2010; Li et al, 2012;
Sparkman and Li, 2012; Swalve and Li, 2012; Zhang and Li,
2012). It also avoided the floor effect (ie, a high dose may
cause a maximal avoidance disruption, leaving no room to
show a sensitization or tolerance effect).
Experiment 2: CLZ Tolerance Induced in Adolescence
and Assessed in Adolescence
This experiment examined whether repeated CLZ treatment
could induce a tolerance effect in adolescent rats in the CAR
model as previously found in adult rats (Li et al, 2010; Li
et al, 2012). The basic procedure was identical to that of
Experiment 1, with the exceptions that 27 adolescent rats
were used and 2 doses of CLZ (10 and 20mg/kg, sc) were
administered during the adolescence period. CLZ 5.0mg/kg
was used as a challenge dose during the tolerance
assessment test (BP 50). The three groups were: vehicle
(sterile water, n¼ 9), CLZ 10mg/kg (CLZ 10, n¼ 9), and
CLZ 20mg/kg (CLZ 20, n¼ 9).
Experiment 3: OLZ Sensitization Induced in
Adolescence and Assessed in Adulthood
This experiment examined whether the sensitization effect
induced by repeated OLZ treatment to adolescent rats in the
CAR model persisted throughout the adolescence period and
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into adulthood. It consisted of the following three components:
avoidance training/induction of OLZ sensitization during
adolescence, sensitization assessment during adulthood,
and PPI assessment. Table 1 details the timeline of events.
Avoidance training/induction of OLZ sensitization during
adolescence. The basic procedure was identical to that of
Experiment 1. Forty adolescent rats (BP 31) were used, of
which 32 were trained for conditioned avoidance respond-
ing for 10 consecutive days/sessions. The remaining eight
rats served as a control group (termed the CS-only group)
for the training effect. They were subjected to the same CAR
procedure, with the only exception that no shock was ever
given, thus they were not trained for CAR.
At the end of the training session (BP 43), the 32 trained
rats were matched and randomly assigned to one of three
groups: vehicle (sterile water, n¼ 11), OLZ 1.0 (n¼ 10), and
OLZ 2.0 (n¼ 11), and tested daily for avoidance response
for 5 consecutive days. The CS-only rats (n¼ 8) were also
tested under the same condition under vehicle.
Sensitization assessment in adulthood on P 76 and
92. Rats remained in their home cages untilBP 68, when
all rats were returned to the CAR boxes for one habituation
session, followed by 7 days of CAR training/retraining to
ensure all groups had a comparable level of avoidance
responding before the sensitization assessment. The CS-
only group was also trained for CAR. The OLZ sensitization
was assessed 1 day after the seventh training session (BP
76), with all rats being injected with a challenge dose of OLZ
0.5mg/kg. On P 90 and 91, all rats were given two CAR
retraining sessions (the first under the CS-only and the
second under the CS–US condition) to bring their
avoidance back to the predrug level. The second OLZ
sensitization test was conducted 1 day later under the same
challenge dose of OLZ (0.5mg/kg).
PPI assessment. A total of three PPI tests were conducted
throughout the developmental period. The first one was
done during the late adolescence period (B P 48, 1 day after
the 5 drug test days), the second one during the early
adulthood period (BP 67, 2 days before the CAR
retraining). The third one (BP 77) was conducted 1 day
after the sensitization test in the CAR.
The PPI test procedure was adapted from Culm and
Hammer (2004). Each session lasted approximately 18min
and began with a 5-min period of 70 dB background noise
(which continued throughout the duration of the session)
followed by four different trial types: PULSE ALONE trials
and three types of PREPULSEþ PULSE trials, which
consisted of a 20ms 73, 76, or 82 dB prepulse (3, 6, and
12 dB above background) later followed by 100ms of 120 dB
pulse. Each session was divided into four blocks. Blocks 1
and 4 were identical, each consisting of four PULSE ALONE
trials. Blocks 2 and 3 were also identical and each consisted
of eight PULSE ALONE trials and five of each PREPULSEþ
PULSE trial type. A total of 54 trials were presented during
each test session. Trials within each block were presented in
a pseudorandom order and were separated by a variable
intertrial interval averaging 15 s (ranging from 9 to 21 s).
Startle magnitude was defined as the maximum force
(measured in Newtons) applied by the rat to the startle
apparatus recorded over a period of 100ms beginning at the
onset of the pulse stimulus. Between each stimulus trial,
100ms of activity was recorded when no stimulus was
present. These trials were called NOSTIM trials and were
not included in the calculation of intertrial intervals.
Responses recorded during NOSTIM trials are considered
a measure of gross motor activity within the PPI boxes.
Startle responses from testing blocks 2 and 3 were used to
calculate %PPI for each acoustic prepulse trial type:
%PPI¼ 100 Average startle response to PREPULSE + PULSE trials
Average startle response to PULSE ALONE trials
 
x100
 
Experiment 4: CLZ Tolerance Induced in Adolescence
and Assessed in Adulthood
This experiment examined whether the tolerance effect
induced by repeated CLZ treatment to adolescent rats in the
CAR model persisted throughout the adolescence period
and into adulthood. The basic procedure was identical to
that of Experiment 3, with the exceptions that two doses of
CLZ (10 and 20mg/kg, sc) instead of OLZ were adminis-
tered during the adolescence period, and the challenge dose
of CLZ (5.0mg/kg) was used during the tolerance assess-
ment tests (see Table 1). The four groups were: vehicle
(sterile water, n¼ 11), CLZ 10 (n¼ 10), CLZ 20 (n¼ 11), and
CS-only (sterile water, n¼ 8).
Statistical Analysis
All data were expressed as meanþ SEM. Avoidance data
from the five drug test sessions were analyzed using a
factorial repeated measures analysis of variance (ANOVA)
with the between-subjects factor being drug group and the
within-subjects factor being test day, followed by post hoc
LSD tests. Data from the retraining/predrug days and from
the challenge tests were analyzed by a one-way ANOVA
Table 1 Timeline of Events Occurred in Experiment 3 and 4
Days of
study
Approximate
age (years)
Manipulation
1–2 PND 31–32 Habituation to CAR boxes (30min/day)
3–12 PND 33–42 10 Days of CAR training (CS–US)
13–17 PND 43–47 5 Days of drug testing (CS-only)
18 PND 48 1st PPI test
19–36 PND 49–66 Rest
37 PND 67 2nd PPI test
38 PND 68 Habituation to CAR boxes (30min/day)
39–45 PND 69–75 7 days of CAR retraining (CS–US)
46 PND 76 1st drug challenge test (CS-only): OLZ
0.50 mg/kg, CLZ 5.0mg/kg
47 PND 77 3rd PPI test
48–59 PND 78–89 Rest
60 PND 90 1st retraining (CS-only)
61 PND 91 2nd retraining (CS–US)
62 PND 92 2nd drug challenge test (CS-only): OLZ
0.50mg/kg, CLZ 5.0mg/kg
The bold text highlight the critical steps of the experiments.
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followed by post hoc LSD tests (for more than three groups).
The %PPI data were presented separately for three prepulse
intensities (eg, 73, 76, and 82 dB) and were analyzed using
repeated measures ANOVAs with drug treatment group as a
between-subjects factor and prepulse level as a within-
subjects factor. For all analyses, po0.05 was considered
statistically significant.
RESULTS
Experiment 1: OLZ Sensitization Induced in
Adolescence and Assessed in Adolescence
Avoidance training and induction of OLZ sensitization.
Avoidance response: Figure 1a shows the number of
avoidance responses on the last training (predrug) day
and five drug test days. There was no group difference on
the last training day. Throughout the drug test phase, OLZ
treatment disrupted avoidance response persistently. Re-
peated measures ANOVA revealed a main effect of group,
F(2, 26)¼ 31.437, po0.001 and day, F(4, 104)¼ 5.105,
p¼ 0.001, but no significant group day interaction. Post
hoc LSD tests revealed that the two OLZ groups differed
significantly from the VEH group, all po0.001, although
they did not differ significantly from each other.
22 kHz USV: OLZ also decreased the number of 22 kHz
USV (Supplementary Table S1). On the predrug day, there
was no significant group difference. During the drug test
days, the two OLZ groups had fewer 22 kHz USVs in
comparison with the VEH group, especially on the first test
day. Repeated measures ANOVA revealed a main effect of
day, F(4, 104)¼ 3.860, p¼ 0.006 and a significant group
day interaction, F(8, 104)¼ 2.982, p¼ 0.005. One-way
ANOVAs on each test day revealed that only on the first
test day did the OLZ 2.0 group show significantly fewer USV
counts than the VEH group, p¼ 0.037.
Intertrial crossing: Unexpectedly, the OLZ 1.0 group had
more intertrial crossings on the last training day than the
other two groups, po0.007 (Figure 1b). Throughout the
drug test phase, OLZ treatment progressively suppressed
the intertrial crossing. Repeated measures ANOVA revealed
a main effect of group, F(2, 26)¼ 57.450, po0.001, a main
effect of day, F(4, 104)¼ 12.528, po0.001, and a significant
group day interaction, F(8, 104)¼ 4.239, po0.001. Post
hoc LSD tests revealed that the two OLZ groups differed
significantly from the VEH group, all po0.001, although
they did not differ significantly from each other.
OLZ sensitization assessment.
Avoidance response: Figure 1c shows the number of
avoidance responses on the second retraining (predrug) day
and the OLZ sensitization test day (BP 50). Before the OLZ
challenge, there was no significant group difference. On the
challenge day when all rats were injected with OLZ 0.5mg/kg,
the two OLZ groups made fewer avoidance responses than
the VEH group. One-way ANOVA confirmed this observation,
as there was a significant effect of group, F(2, 26)¼ 3.749,
p¼ 0.037. Post hoc LSD tests showed that the OLZ 2.0 and
OLZ 1.0 groups were significantly different from the VEH
group, p¼ 0.042 and 0.018, respectively.
22 kHz USV and intertrial crossing: No significant group
difference was detected on the number of 22 kHz USVs on
the predrug day and on the challenge day (Supplementary
Table S1). Similarly, no significant group difference was
detected on the intertrial crossing on the predrug day and
on the challenge day (Figure 1d).
Collectively, the above results indicate that repeated OLZ
treatment induced a robust sensitization effect during
adolescence. This effect was dose-dependent and specific
to avoidance response, but not to 22 kHz USVs and
intertrial crossing.
Experiment 2: CLZ Tolerance Induced in Adolescence
and Assessed in Adolescence
Avoidance training and induction of CLZ tolerance.
Avoidance response: Figure 2a shows the number of
avoidance responses on the last training day (predrug)
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Figure 1 Olanzapine (OLZ) sensitization induced in adolescence and assessed in adolescence. Number of avoidance responses (a) and intertrial crossing
(b) made by the rats from the OLZ (1.0mg/kg), OLZ (2.0mg/kg), and vehicle (VEH) groups on the last training (predrug) day and throughout the five drug
test days are expressed as meanþ SEM. The same measures on the second retraining (predrug) day and the OLZ sensitization assessment day are also
expressed as meanþ SEM and depicted in c and d, respectively. *po0.05 relative to the VEH group; #po0.05 relative to the OLZ 2.0 and VEH groups.
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and five drug test days. There was no group difference on the
last training day. Throughout the drug test days, CLZ
treatment severely disrupted avoidance response. Repeated
measures ANOVA revealed a main effect of group, F(2, 24)
¼ 26.498, po0.001 and day, F(4, 96)¼ 2.772, p¼ 0.031,
and a significant group day interaction, F(8, 96)¼ 6.016,
po0.001. Post hoc LSD tests revealed that the two CLZ groups
differed significantly from the VEH group, all po0.001,
although they did not differ significantly from each other.
22 kHz USV: On the last training day (Supplementary
Table S2), there was no significant group difference. During
the drug test period, repeated measures ANOVA also failed
to find a main effect of group, day, nor their interaction.
Post hoc LSD tests also failed to find any group difference,
p40.056.
Intertrial crossing: There was no significant group
difference on the last training day (Figure 2b). Throughout
the drug test phase, CLZ treatment suppressed the intertrial
crossing. Repeated measures ANOVA revealed a main effect of
group, F(2, 24)¼ 44.520, po0.001 and a significant group
day interaction, F(8, 96)¼ 4.170, po0.001, but no main effect
of day. Post hoc LSD tests revealed that the two CLZ groups
differed significantly from the VEH group, all po0.001,
although they did not differ significantly from each other.
CLZ tolerance assessment.
Avoidance response: Figure 2c shows the number of
avoidance responses on the second retraining (predrug) day
and the CLZ tolerance test day (BP 50). Before the CLZ
challenge, there was no significant group difference. On
the challenge day when all rats were injected with CLZ
5.0mg/kg, the two CLZ groups made more avoidance
responses than the VEH group. One-way ANOVA revealed a
significant effect of group, F(2, 24)¼ 11.436, po0.001. Post
hoc LSD tests showed that the CLZ 10 and CLZ 20 groups
were significantly different from the VEH group, p¼ 0.025
and po0.001, respectively, and the CLZ 20 group was also
significantly different from the CLZ 10 group, p¼ 0.025.
22 kHz USV and intertrial crossing: The number of 22 kHz
USV was not significantly different among groups on the
predrug day and on the challenge day (Supplementary Table
S2). Similarly, no significant group difference was detected
on the intertrial crossing on the predrug day (Figure 2d).
However, there was a significant group difference on the
challenge test, F(2, 24)¼ 8.401, p¼ 0.002. Post hoc tests
showed that the CLZ 20 group made more crossings than
the VEH group, po0.001, whereas the CLZ 10 group was
only marginally different from the VEH group, p¼ 0.053,
and marginally different from the CLZ 20 group, p¼ 0.050.
Overall, these results indicate that repeated CLZ treat-
ment induced a robust tolerance effect during adolescence.
This effect was dose-dependent and specific to avoidance
response, but not to 22 kHz USV. It was also manifested in
the intertrial crossings.
Experiment 3: OLZ Sensitization Induced in
Adolescence and Assessed in Adulthood
Avoidance response during adolescence: Figure 3a shows the
number of avoidance responses made by the rats in the four
groups on the last adolescence training day and throughout
the five drug test days. At the end of the training phase, rats
trained in the CAR had a significant higher level of
avoidance responding than the CS-only rats (the average
was 13.22þ 2.16 vs 3.13þ 1.03, respectively, t38¼  4.227,
po0.001). During the drug test days, the two OLZ groups
and the CS-only group had fewer avoidance responses,
whereas the VEH group maintained a high level of
avoidance responding. Repeated measures ANOVA revealed
a main effect of group, F(3, 36)¼ 13.673, po0.001; day,
F(4, 144)¼ 2.592, p¼ 0.039, and a significant group day
interaction, F(12, 144)¼ 3.506, po0.001. Post hoc LSD tests
revealed that the two OLZ groups were significantly
different from the VEH group, all po0.001, but not
significantly different from the CS-only group. The CS-only
group also differed significantly from the VEH group,
p¼ 0.001.
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Figure 2 Clozapine (CLZ) tolerance induced in adolescence and assessed in adolescence. Number of avoidance responses (a) and intertrial crossing (b)
made by the rats from the CLZ (10.0mg/kg), CLZ (20.0mg/kg), and vehicle (VEH) groups on the last training (predrug) day and throughout the five drug
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22 kHz USV: On the last training day, rats trained in the
CAR emitted significantly more 22 kHz USV than the CS-only
rats (the average was 1271.56þ 160.34 vs 1.88þ 1.09,
respectively, t31¼  7.918, po0.001; Supplementary Table
S3). During the drug test days, the two OLZ groups and the
CS-only group emitted fewer 22 kHz USV in comparison
with the VEH group. Repeated measures ANOVA revealed a
main effect of group, F(3, 36)¼ 12.297, po0.001; day,
F(4, 144)¼ 16.126, po0.001, and a significant group day
interaction, F(12, 144)¼ 9.443, po0.001. Post hoc tests
revealed that the two OLZ groups were significantly different
from the VEH group, all po0.001, but not significantly
different from the CS-only group. The CS-only group also
differed significantly from the VEH group, po0.001.
Intertrial crossing: No significant group difference was
found on the intertrial crossing on the last training day
(Figure 3b). During the drug test days, the two OLZ groups
and the CS-only group had fewer intertrial crossings in
comparison with the VEH group. Repeated measures
ANOVA revealed a main effect of group, F(3, 36)¼ 40.108,
po0.001; day, F(4, 144)¼ 5.971, po0.001, and a significant
group day interaction, F(12, 144)¼ 6.334, po0.001. Post
hoc tests revealed that the two OLZ groups and the CS-only
group were significantly different from the VEH group, all
po0.001. The two OLZ groups were also significantly
different from the CS-only group, po0.038.
Sensitization assessment in adulthood on P 76 and 92.
Avoidance response on P 76: Figure 3c shows the number
of avoidance responses on the seventh retraining day and
the first sensitization test day (BP 76). Before the OLZ
challenge, there was no significant group difference. On
the challenge day when all rats were injected with OLZ
0.5mg/kg, the two OLZ groups made fewer avoidance
responses than the other two OLZ-naive groups.
One-way ANOVA revealed a significant effect of group,
F(3, 36)¼ 3.998, p¼ 0.015. Post hoc LSD tests showed that
the OLZ 2.0 group was significantly different from the CS-
only group, p¼ 0.002 and the VEH group, p¼ 0.020,
respectively. However, the OLZ 1.0 group was not
significantly different from the other groups.
22 kHz USV and intertrial crossing on P 76: No significant
group difference was detected on the number of 22 kHz USV
on the predrug day and on the challenge day (Supple-
mentary Table S3). On the intertrial crossing (Figure 3d), no
significant group difference was detected on the predrug
day. On the challenge day, one-way ANOVA showed a main
effect of group, F(3, 36)¼ 3.274, p¼ 0.032. Post hoc tests
showed that the OLZ 2.0 group was significantly different
from the other three groups, po0.024.
Avoidance response on P 92: Figure 3e shows the number
of avoidance responses on the predrug day and the second
sensitization test day (BP 92). Before the OLZ challenge,
there was no significant group difference. On the challenge
day, the two OLZ groups made fewer avoidance responses
than the other two groups treated with vehicle during the
adolescence period. One-way ANOVA revealed a significant
effect of group, F(3, 36)¼ 6.407, p¼ 0.001. Post hoc tests
showed that the OLZ 2.0 group was significantly different
from the CS-only group, p¼ 0.007 and the VEH group,
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Figure 3 Olanzapine (OLZ) sensitization induced in adolescence and assessed in adulthood. Number of avoidance responses (a) and intertrial crossing
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po0.001, respectively. The OLZ 1.0 group was also
significantly different from the VEH group, p¼ 0.006, and
marginally different from the CS-only group, p¼ 0.067.
22 kHz USV and intertrial crossing on P 92: There was
no significant group difference on the 22 kHz USV on
the predrug day and on the challenge day (Supplementary
Table S3). Similarly, no significant group difference was
detected on the intertrial crossing on the predrug day
(Figure 3f). On the challenge day, one-way ANOVA showed
a main effect of group, F(3, 36)¼ 5.840, p¼ 0.002. Post hoc
tests showed that the OLZ 2.0 group was significantly dif-
ferent from the VEH group, po0.001 and the CS-only
group, p¼ 0.048. The OLZ 1.0 group was also significantly
different from the VEH group, p¼ 0.019.
Collectively, the above findings indicate that repeated
OLZ treatment in adolescence induced a strong sensitiza-
tion effect in adulthood that was dose-dependent, long-
lasting, and behavioral specific, as it was only shown in
avoidance response and intertrial crossing, but not in
22 kHz USV. The main difference between the OLZ
sensitization assessed during adolescence and the one
assessed during adulthood was that it also manifested itself
in the intertrial crossing in adulthood.
PPI assessment. PPI data from the 3 time points of testing
(BP 48, 67 and 77) did not reveal any significant group
difference (Supplemetary Figure S1A, 1B and 1C). The
group prepulse level interaction was only significant on P
67, p¼ 0.012. However, one-way ANOVA failed to find any
significant group difference at each prepulse level. These
findings suggest that repeated OLZ treatment did not
significantly impair the sensorimotor gating ability, a
finding consistent with a previous report (Llorente-Berzal
et al, 2012).
Experiment 4: CLZ Tolerance Induced in Adolescence
and Assessed in Adulthood
Avoidance response during adolescence: Figure 4a shows the
number of avoidance responses made by the rats in the four
groups on the last adolescence training day and throughout
the five drug test sessions. At the end of the training phase,
rats trained in the CAR had a significantly higher level of
avoidance responding than the CS-only rats (the average
was 13.84þ 2.36 vs 6.63þ 1.15, respectively, t38¼  2.747,
p¼ 0.009). During the drug test days, the two CLZ groups
and the CS-only group made fewer avoidance responses,
whereas the VEH group maintained a high level of
avoidance responding. Repeated measures ANOVA revealed
a main effect of group, F(3, 36)¼ 23.111, po0.001, but no
main effect of day nor group day interaction. Post hoc
LSD tests revealed that the two CLZ groups were
significantly different from the VEH group, all po0.001,
but not significantly different from the CS-only group. The
CS-only group also differed significantly from the VEH
group, po0.001.
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Figure 4 Clozapine (CLZ) tolerance induced in adolescence and assessed in adulthood. Number of avoidance responses (a) and intertrial crossing (b)
made by the rats from the CS-only, CLZ (10.0mg/kg), CLZ (20.0mg/kg), and vehicle (VEH) groups on the last training (predrug) day and throughout the five
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22 kHz USV: On the last training day, rats trained in the
CAR emitted significantly more 22 kHz USV than the CS-
only rats (the average was 625.38þ 143.65 vs 1.63þ 0.50,
respectively, t31¼  4.342, po0.001; Supplementary Table
S4). During the drug test days, the two CLZ groups and the
CS-only group had fewer 22 kHz USV compared with the
VEH group. Repeated measures ANOVA revealed a main
effect of group, F(3, 36)¼ 5.721, p¼ 0.003, but no main
effect of day nor group day interaction. Post hoc tests
revealed that the two CLZ groups were significantly
different from the VEH group, all po0.003, but not
significantly different from the CS-only group. The CS-only
group also differed significantly from the VEH group,
p¼ 0.003.
Intertrial crossing: There was no significant group
difference on the intertrial crossing on the last training
day. During the drug test days, the two CLZ groups and the
CS-only group had fewer intertrial crossings in comparison
with the VEH group (Figure 4b). Repeated measures
ANOVA revealed a main effect of group, F(3, 36)¼ 42.
029, po0.001; day, F(4, 144)¼ 3.984, p¼ 0.004, but no
significant group day interaction. Post hoc tests revealed
that the two CLZ groups and the CS-only group were
significantly different from the VEH group, all po0.001.
The two CLZ groups were also significantly different from
the CS-only group, po0.027.
Tolerance assessment in adulthood on P 76 and 92.
Avoidance response on P 76: Figure 4c shows the number
of avoidance responses on the seventh retraining day and
the first tolerance test day (BP 76). Before the CLZ
challenge, there was no significant group difference. On the
challenge day when all rats were injected with CLZ 5.0mg/
kg, rats from all four groups exhibited a similar low level of
avoidance responding. One-way ANOVA did not find a
significant main effect of group.
22 kHz USV and intertrial crossing on P 76: No significant
group difference was detected on the 22 kHz USV, on the
predrug day and on the challenge day (Supplementary Table
S4). Similarly, on the intertrial crossing (Figure 4d) there
was no significant group difference on the predrug day,
although a post-hoc two group comparison found that the
CS-only group had significantly fewer crossings than the
vehicle group, p¼ 0.035. On the challenge day, one-way
ANOVA showed a main effect of group, F(3, 36)¼ 2.893,
p¼ 0.049. Post hoc tests showed that the CLZ 20 group had
significantly higher crossings than the other three groups,
po0.039.
Avoidance response on P 92: Figure 4e shows the number
of avoidance responses, on the predrug day and the second
tolerance test day (BP 92). Once again, no significant group
difference was detected on both days.
22 kHz USV and intertrial crossing on P 92: No signi-
ficant group difference on the 22 kHz USV was detected on
the predrug day and on the challenge day (Supplementary
Table S4). On the intertrial crossing (Figure 4f),
there was a significant group difference on the predrug
day, F(3, 36)¼ 3.151, p¼ 0.037, with the CS-only group
made fewer crossings than the other three groups, po0.049.
On the challenge day, the group difference was not
significant.
Collectively, the above findings indicate that repeated
CLZ treatment during adolescence did not induce a robust
tolerance effect in avoidance response during adulthood at
both time points. The CLZ tolerance effect was only found
in the intertrial crossing on BP 76. As the three measures
(avoidance, 22 kHz USV, and intertrial crossing) in the CAR
task may represent three putative behavioral effects of CLZ
(ie, antipsychotic, anxiolytic, and motor impairment/
sedative effect), results from this experiment suggest that
adolescent CLZ treatment induced a tolerance to its motor
impairment/sedative effect, whereas its antipsychotic and
anxiolytic effects did not undergo tolerance.
PPI assessment. PPI data from the 3 time points of testing
(BP 48, 67 and 77) did not reveal any significant group
difference (Supplementary Figure S2A, 2B and 2C). The
group prepulse level interactions were also not significant.
These findings suggest that repeated CLZ treatment did not
significantly impair the sensorimotor gating ability.
DISCUSSION
Although onset of schizophrenia typically occurs in late
adolescence, most preclinical work on the behavioral effects
and mechanisms of action of antipsychotic drugs has been
often conducted on adult animals. The present study asked
two critical questions as follows: (1) Can OLZ sensitization
and CLZ tolerance be induced in adolescent rats? (2) Can
OLZ sensitization and CLZ tolerance induced in adoles-
cence persist into adulthood? The answer to both questions
is yes. We demonstrated that OLZ sensitization and CLZ
tolerance could be induced in adolescent rats using the
same procedure (ie, an induction phase followed by a
challenge test) as employed in adult rats (Li et al, 2004; Li
et al, 2007; Li et al, 2009a; Li et al, 2009b; Li et al, 2010;
Mead and Li, 2010; Li et al, 2012; Zhang and Li, 2012). They
mainly manifested in the avoidance response (a behavioral
measure of antipsychotic activity) and/or intertrial crossing
(a behavioral measure of motor function/sedation), but not
in the 22 kHz USV (an index of anxiolytic property),
suggesting that they are behaviorally specific (Stewart and
Badiani, 1993). Furthermore, the magnitude of both effects
depended on the initial treatment doses of OLZ and CLZ,
and the persistence of such effects also depended on the
specific drugs (ie, CLZ vs OLZ). In this sense, these long-
term effects may reflect the intrinsic pharmacological
properties of OLZ and CLZ.
The most remarkable findings of the present study were
the demonstrations of the long-lasting OLZ sensitization
and the transient CLZ tolerance across the adolescence and
adulthood developmental periods in the CAR model. To the
best of our knowledge, this is the first demonstration of
such effects in a valid behavioral test of antipsychotic
activity. The majority of preclinical research on adolescence
antipsychotic treatment has often focused on two issues.
One is the age difference in psychopharmacological
responsiveness and brain responses to antipsychotics
between adolescent animals and adult ones (Spear and
Brake, 1983; Moran-Gates et al, 2006; Wiley, 2008; Choi
et al, 2010). The common approach is to compare animals
in different age groups on their behavioral responses
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(eg, locomotor activity, catalepsy; Wiley and Evans, 2008)
and brain responses (eg, dopamine and 5-HT receptors;
Moran-Gates et al, 2006; Choi et al, 2010) to various
antipsychotic treatments, without tracking changes across
the different development stages. The second issue of
interest is the long-term behavioral and brain consequences
of antipsychotic treatment in adolescence (Llorente-Berzal
et al, 2012). One focal area is the potential preventive or
treatment effects of adolescence antipsychotic exposure on
behavioral and brain abnormalities in animal models of
schizophrenia (Piontkewitz et al, 2009; Piontkewitz et al,
2011). The present study differed from those studies in that
it focused on how antipsychotic treatment during adoles-
cence alters antipsychotic response in adolescence and
beyond (eg, adulthood). Indeed, very little prior research
has been done on this topic. We could only find one study
that showed a haloperidol-induced sensitization effect on
catalepsy (Spear et al, 1980). The lack of research on this
topic is not surprising given that antipsychotic sensitization
and tolerance are relatively newly recognized phenomena
even in adult animals (Li et al, 2010; Zhang and Li, 2012).
OLZ and other antipsychotic drugs, such as haloperidol
and risperidone, often induce a sensitization effect in a
variety of animal behaviors. Besides the CAR test, it has
been reported in a catalepsy test (Lanis and Schmidt, 2001;
Amtage and Schmidt, 2003; Klein and Schmidt, 2003), a
PCP-induced hyperlocomotion test (Sun et al, 2009; Zhang
and Li, 2012), a PPI of acoustic startle procedure (Li et al,
2011), an operant responding procedure (Varvel et al,
2002), as well as in the metabolic effect (Boyda et al, 2012).
In contrast, CLZ often induces a tolerance effect (Li et al,
2010). CLZ-induced tolerance has also been observed in a
drug discrimination task (Goudie et al, 2007a; Goudie et al,
2007b) and in a PCP-induced hyperlocomotion (unpub-
lished observations). In the present study, we noted that
CLZ tolerance seems to be weaker than OLZ sensitization in
terms of its persistence. It only manifested in the intertrial
crossing on BP 76 but not on BP 92, whereas OLZ
sensitization manifested in both avoidance response and
intertrial crossing, and at both time points. What account
for their differences is not entirely clear. On the basis of our
previous work on the neuroceptor mechanisms of OLZ
sensitization and CLZ tolerance in adult rats (Li et al, 2010;
Li et al, 2012), we speculate that their differential (even
opposing) actions on dopamine D2/3 receptors may be one
of the factors, as we show that pretreatment of quinpirole, a
selective D2/D3 dopaminergic receptor agonist, attenuated
OLZ sensitization but enhanced CLZ tolerance on avoidance
response. Future work should investigate the role of
dopamine D2/3 receptors in the mediation of OLZ sensitiza-
tion and CLZ tolerance in adolescence.
In the present study as well as our previous ones (Sun
et al, 2009; Li et al, 2010), we have observed no differences
in behavioral responsiveness to OLZ and CLZ in the
induction phase (ie, the repeated drug treatment period),
but differences in the expression phase (ie, the challenge
test). For example, during the drug treatment period in both
the CAR and the PCP-induced hyperlocomotion model
(ie, the induction phase), repeated OLZ and CLZ treatment
persistently inhibited avoidance response and PCP-induced
hyperlocomotion. OLZ and CLZ did not differ from each
other (Sun et al, 2009; Li et al, 2010). Only in the later
challenge test (ie, the expression phase) did we observe the
pattern differences between OLZ and CLZ. Other psycho-
tropic drugs have also shown differential effects in different
phases (Stewart and Badiani, 1993). These findings suggest
that the expression of OLZ sensitization or CLZ tolerance
does not necessarily require the manifestation of such an
effect during the induction phase. As there is evidence
suggesting that the induction and expression of behavioral
sensitization involve independent neural systems (Cador
et al, 1995), it is likely that the induction and expression of
OLZ sensitization and CLZ tolerance may also involve
different processes and mechanisms that affect ongoing
behaviors differentially.
In our previous rat CAR studies (Mead et al, 2008; Sun
et al, 2010), we have shown that OLZ and CLZ as atypical
antipsychotics also possess an intrinsic anxiolytic property
as revealed by their ability to decrease various behavioral
and physiological measures of anxiety/fear (eg, stress-
induced hyperthermia, 22 kHz USV, startle reactivity,
defecation, and urination), in addition to their antipsycho-
tic property as indexed by their anti-avoidance effect. These
two properties seem dissociable and might be mediated by
their different molecular actions. For example, OLZ-
induced elevations in allopregnanolone is shown to mediate
its anxiolytic effect (Frye and Seliga, 2003), whereas its
action on D2 receptors is responsible for its antipsychotic
effect (Kapur et al, 1998). Interestingly, the present study
added another piece of evidence for the dissociated
anxiolytic and antipsychotic actions of OLZ and CLZ, as
both OLZ-induced sensitization and CLZ-induced tolerance
were selective to their putative antipsychotic effect (eg, anti-
avoidance) and not to their anxiolytic effect (eg, a
decreasing effect on 22 kHz USV). Different behavioral
effects of a drug undergo different time courses of change
with repeated drug administration are certainly not new
(Stewart and Badiani, 1993).
Adolescence is a period in which the brain undergoes
dramatic transitions and re-organization (Brenhouse and
Andersen, 2011). For example, adolescents tend to over-
express various neuroreceptors (eg, dopaminergic, adre-
nergic, serotonergic) followed by pruning to adult levels (an
inverted U-shape curve of development). Both dopamine
receptors (eg, D1, D2) and serotonergic receptors (eg, 5-
HT1A, 5-HT2A) that are implicated in the mechanisms of
action of antipsychotic drugs are reported to be expressed
at higher levels in various brain areas (eg, cerebral cortex,
hippocampus, dorsal and ventral striatum, and septum)
during adolescence than in adulthood (Lidow et al, 1991;
Teicher et al, 1995; Tarazi et al, 1998; Andersen et al, 2000),
and antipsychotic exposure alters these neuroreceptors in
unique ways not seen in adult animals (Moran-Gates et al,
2006; Choi et al, 2009; Choi et al, 2010). For instance,
Moran-Gates et al (2006) found that repeated administra-
tion of OLZ (5mg/kg, once daily) and CLZ (20mg/kg, twice
daily) from P 22 to P 42, all decreased D1 receptors in
dorsolateral frontal and medial prefrontal cortex of
adolescent, but not adult rats. In contrast, both drugs
increased D2 receptors in the medial prefrontal cortex of
adult, but not adolescent rats (Moran-Gates et al, 2006).
OLZ, but not CLZ, also increased D2 receptor levels in
hippocampus, and D4 levels in nucleus accumbens and
caudate-putamen in both juvenile and adult rats. The
Olanzapine sensitization and clozapine tolerance
J Qiao et al
522
Neuropsychopharmacology
finding that OLZ sensitization and CLZ tolerance had
survived the adolescent period indicates that certain drug-
induced brain changes may be relatively permanent. One
important line of research is to delineate how antipsychotics
induce brain changes and identify where these changes
take place.
As antipsychotic drugs are being increasingly used in
children and adolescents in the past two decades (Olfson
et al, 2006), findings from this study are important for the
understanding of the impacts of adolescence antipsychotic
treatment on the brain and behavioral developments and
associated behavioral and neurobiological mechanisms. Our
findings suggest that antipsychotic exposure during adoles-
cence could alter the trajectory of the brain and behavioral
development of pediatric patients, which in turn may
change their later response to drug treatment as adults.
Currently, antipsychotic drugs are often used in the short
term to calm disturbed children with irritability associated
with autism, tic disorders, obsessive-compulsive disorder,
posttraumatic stress disorder, and aggression (Correll et al,
2011). The long-term consequences of such exposures on
psychological functions and other aspects of brain matura-
tion at various ages have not been systematically investi-
gated and are less well understood. The present study points
out that even 5 days of drug exposure could induce a long-
lasting effect that persists into adulthood. Thus, for the
clinical practice, such a long-term consequence of adoles-
cence antipsychotic treatment needs to be better understood
and monitored, as many pediatric patients need medica-
tions after they become adults.
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